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OBJECTIVE— Bimodality in the distribution of glucose has been used to define the cut point
for the diagnosis of diabetes. Previous studies on bimodality have primarily been in populations
with a high prevalence of type 2 diabetes, including one study in a white Caucasian population.
All studies included participants with known diabetes. The aim of this study was to assess
whether a bimodal structure is a general phenomenon in fasting plasma glucose (FPG) and 2-h
plasma glucose that is useful for deriving a common cut point for diabetes in populations of
different origin, both including and excluding known diabetes.
RESEARCH DESIGN AND METHODS— The Evaluation of Screening and Early De-
tection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) project is an
international collaboration pooling surveys from all continents. These studies include surveys in
which plasma glucose was measured during an oral glucose tolerance test; in total, 43 studies
(135,383 participants) from 27 countries were included. A mixture of two normal distributions
was fitted to plasma glucose levels, and a cut point for normal glycemia was estimated as their
intersection. In populations with a biologically meaningful cut point, bimodality was tested for
significance.
RESULTS— Distributions of FPG and 2-h plasma glucose did not, in general, produce bi-
modal structures useful for deriving cut points for diabetes. When present, the cut points
produced were inconsistent over geographical regions.
CONCLUSIONS— Deriving cut points for normal glycemia from distributions of FPG and
2-h plasma glucose does not appear to be suitable for defining diagnostic cut points for diabetes.
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B imodality in glucose distributionhas been reported in a number ofpopulations with a high prevalence
of diabetes, including the American Pima
Indians (1) and the Micronesian popula-
tion of Nauru (2). This observation was an
important component in defining the
1980 World Health Organization (WHO)
diagnostic criteria for diabetes together
with thresholds for diabetes-specific
microvascular complications such as
retinopathy. Subsequent studies of
bimodality in Egypt (3,4) and in Mexican
Americans (5) rendered further support
for the WHO 1980 and 1985 diagnostic
criteria for diabetes (6,7).
Later, the presence of bimodality in
glucose was also found in the high-
diabetes-prevalence populations in Papua
New Guinea (8) and in South African In-
dians (9). Few studies on bimodality have
been conducted in populations with low
diabetes prevalence (10–12). Here, bimo-
dality was shown in 2-h plasma glucose
values but with differing cut points for
normal glycemia. Only one study has
demonstrated bimodality in white Cauca-
sians (13).
These findings in diverse populations
suggest that bimodality in glucose is uni-
versal. However, all of these studies in-
cluded participants with known diabetes.
Patients with diabetes are treated (lifestyle
and medication) to lower glycemic levels.
Including these patients in the analysis in-
troduces a systematic treatment bias,
something that could either enhance or
diminish the bimodal structure of data.
The aim of this study was to assess
whether distributions of plasma glucose
(fasting and 2 h), in general, give rise to a
bimodal structure, which is useful for de-
riving a cut point for diabetes in popula-
tions of different origin, both including
and excluding participants with known
diabetes and, if present, to assess whether
the cut point for normal glycemia derived
from such a bimodal structure varied be-
tween populations from different geo-
graphic regions.
RESEARCH DESIGN AND
METHODS— This study is based on
the Evaluation of Screening and Early De-
tection Strategies for Type 2 Diabetes and
Impaired Glucose Tolerance (DETECT-2)
database, a worldwide collaborative study
based on original data from population-
based surveys of 500 participants (14).
The individual studies have been de-
scribed precisely (supplemental data,
available in an online appendix at http://
dx.doi.org/10.2337/dc08-0867). In this
analysis, only studies in which plasma
glucose was measured during a 75-g oral
glucose tolerance test were included.
Participants who had been told by a
doctor they had diabetes or who were re-
ceiving antidiabetes treatment (diet or
medication) were defined as having
known diabetes. All others were classified
according to the WHO 1999 diagnostic
criteria (15). Participants with one glu-
cose value in the nondiabetic range and
missing data for the other glucose value
could not be classified according to the
WHO criteria and were excluded. All
analyses were performed first excluding
and then including participants with
known diabetes. In all surveys, partici-
pants gave their consent for participation
in accordance with the Declaration of
Helsinki.
Statistical methods
Analyses were performed using R version
2.8.0. All analyses were stratified by
country.
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The distributions of both fasting plasma
glucose (FPG) and 2-h plasma glucose are
skewed to the right. To reduce skewness,
glucose values were log transformed before
model fitting. A normal distribution and a
mixture of two normal distributions were
fitted to the log-transformed glucose data.
The probability density function for the
normal distribution is as follows:
f x; ,  
1
2 exp x  
2
22  .
Here,  and  are the mean and SD of x.
We fitted the normal distribution to data
using the maximum likelihood method.
The probability density function for the
mixture model of two normal compo-
nents is as follows:
Table 1—Characteristics of the study populations
Region Country Center n
Known
diabetes (%) SDM (%) Age range Study period
Greenland Greenland B99* 1,142 1.1 9.1 27–86 1998–2002
North Europe U.K. Ely* 1,156 — 7.0 40–69 1990–1992
NHP* 800 2.6 7.6 30–76 1992–1994
Whitehall II 10,270 0.8 1.5 39–63 1991–1993
Finland East-West Finland* 461 12.4 10.8 70–89 1989
FIN–MONICA92 1,929 4.6 3.9 40–64 1992
Vantaa* 613 11.3 6.4 64–66 1990–1991
FINRISK02* 3,767 3.3 8.8 44–75 2002
Sweden NSW–MONICA 3,561 6.8 2.8 25–75 1986–2004
ULSAM*† 1,221 5.7 10.3 69–74 1991–1995
Denmark Glostrup* 695 5.6 3.7 59–62 1996–1997
Inter99* 6,784 2.0 3.9 30–60 1999–2001
Germany KORA* 1,485 8.8 8.0 55–74 1999–2001
Central Europe Holland Hoorn* 2,484 3.5 6.6 49–77 1989–1991
Zutphen* 484 8.1 9.7 70–90 1990
France Paris Prospective* 7,176 2.0 4.3 44–55 1968–1974
Poland PMSDE* 2,838 6.3 7.8 35–77 1998–2000
South Europe Spain Guia* 693 8.9 9.7 30–93 1994–1997
Israel GOH*† 1,291 1.9 7.3 35–69 1976–1982
Eastern Mediterranean and Middle East Egypt Egypt*† 1,451 28.5 9.3 20–89 1992–1993
Africa Mauritius Mauritius* 4,908 6.1 8.4 25–75 1987
Cameroon Cameroon* 1,804 0.4 0.7 24–74 1996
India India CUPS*† 1,259 7.1 4.8 20–87 1996–1998
Dombivli 550 5.5 8.5 31–80 1998–1999
Chennai† 2,182 7.5 6.4 18–94 1993–1995
CURES* 2,350 6.1 9.7 20 2001–2004
Japan Japan Funagata*† 2,154 5.1 3.5 35–89 1992–1997
Asia remaining China Harbin† 1,376 1.5 2.0 40–85 1998
Qingdao 2,061 4.7 9.3 30–74 2002
Indonesia Jakarta*† 1,019 3.5 4.3 14–87 1992–1993
Taiwan Kinmen* 1,456 — 12.6 30–88 1991–1994
Singapore NHS92* 3,568 4.4 6.0 17–69 1992
Korea Korea 10,044 5.7 7.3 37–71 2001–2003
Vietnam Vietnam* 9,122 1.2 2.3 30–65 2002
Australia and New Zealand Australia AusDiab* 11,144 5.1 4.2 25–95 1999–2000
Pacific Islands Nauru Nauru* 868 19.1 14.7 19–81 1987
Tonga Tonga* 472 — 15.0 15–85 1998–2000
Tonga04* 1,016 — 9.3 15–87 2001–2004
Samoa Samoa* 3,285 3.8 7.5 20–90 1978–1991
North America U.S. NHANES III*† 3,105 7.1 9.9 40–74 1988–1994
NHANES II*† 3,814 2.6 5.6 20–74 1976–1980
ARIC, U.S.* 11,596 11.8 10.0 52–70 1996–1999
NHANES99* 5,929 4.8 2.6 12–85 1999–2001
*Centers with measured fasting plasma glucose in individuals with known diabetes. †Centers with measured 2-h plasma glucose in individuals with known diabetes.
‡In NHANES99, SDM is based on fasting values only. ARIC, Atherosclerosis Risk in Communities; AusDiab, Australian Diabetes, Obesity and Lifestyle Study; CUPS,
Chennai Urban Population Study; CURES, Chennai Urban Rural Epidemiology Study; FIN-MONICA, Finland Monitoring of Trends and Determinants in Cardio-
vascular Disease; GOH, Glucose Intolerance Obesity and Hypertension; FINRISK02, FINRISK 2002; KORA, Cooperative Health Research in the Region of Augsburg;
NHANES, National Health and Nutrition Examination Survey; NHS92, 1992 National Health Survey; NHP, Newcastle Heart Project; NSW-MONICA, New South
Wales Monitoring of Trends and Determinants in Cardiovascular Disease; PMSDE, Polish Multicenter Study on Diabetes Epidemiology; ULSAM, Longitudinal Study
of Adult Men.
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fx fx; 1, 1 1  fx; 2, 2.
Here,  and 1   are the mixture pro-
portions with  between zero and unity.
The mixture model was fitted using a
combination of a Newton-type method
and the expectation-maximization (EM)
algorithm (16) (the normalmixEM2comp
function from the Mixtools package in R).
To assess the presence of bimodality,
the mixture model was compared with
the unimodal distribution. The variance
of the two components in the mixture
model may differ. In that case, simulation
results have shown that the limiting func-
tion for the likelihood ratio test is
bounded by 	2 distributions with 4 and 6
degrees of freedom (d.f.) (17). In this
study, P values for significance of the mix-
ture model were based on a 	2 distribu-
tion with 4 d.f. A significance level of 5%
was used.
A cut point for normal glycemia was
calculated as the crossing point of the two
normal distributions in the mixture
model. Approximate CIs for the cut
points were estimated by bootstrapping
(1,000 bootstraps) (18).
The aim of this study was to detect
whether distributions of FPG and 2-h
plasma glucose give two distinct entities
that may be used to separate individuals
into two groups: those having normal or
abnormal glycemia. For this separation to
be biologically meaningful, the cut point
separating these two entities should be
between their modes (1, 2). If not, the
estimated cut point would not be useful
because more than half of the individuals
in the upper entity would have a glucose
level below the cut point, which, conse-
quently, would identify them as having
normal glycemia.
Mixture models were fitted to the glu-
cose values in each country to derive cut
points for normal glycemia. In countries
in which this cut point was biologically
meaningful, the presence of bimodality
was tested. As described in an earlier
study on bimodality (10), the ability of a
fitted mixture model to be statistically su-
perior to a unimodal model depends on
the sample size, the prevalence of diabe-
tes, and the difference between the means
of the two underlying distributions in
units of SDs. In small samples, a lack of
power may prohibit significance of the
mixture model even when bimodality is
truly present. To not be limited by lack of
power, all biologically meaningful cut
points for normal glycemia are reported
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in this article irrespective of the statistical
significance of the mixture model.
RESULTS— This study included
135,383 participants with measurements
of FPG and/or 2-h plasma glucose from
43 studies in 27 different countries cov-
ering 12 different geographic regions. Ta-
ble 1 lists the characteristics of the study
populations.
The prevalence of screen-detected di-
abetes (SDM) ranged from 0.7% in Cam-
eroon to 14.7% in Nauru. Analysis was
done by country, pooling the individual
studies within a country. Because the in-
dividual studies varied in both sex and
age distribution, the pooled data for a
country do not necessarily reflect the age
and sex distribution in that country. Indi-
vidual records have not been weighted in
the analyses.
The proportion of men and the age
range varied among the countries. In
studies including both sexes, men seemed
slightly underrepresented. The Dutch
and German studies were the oldest
(49–89 and 55–74 years, respectively),
whereas the French study was restricted
to the middle-aged (44–55 years) popu-
lation. In the remaining countries, age
range was well represented. In all coun-
tries, prevalence of diabetes increased
with age, with the only exception being
Samoa, where a small decrease was
observed.
Analyses excluding patients with
known diabetes
For FPG, the mixture model resulted in a
biologically meaningful cut point for nor-
mal glycemia in 5 of 27 countries (19%).
Except for Singapore, the mixture model
was also statistically superior to the uni-
modal model; i.e., bimodality was present
(Table 2). The estimated cut points
ranged from 6.1 mmol/l (95% CI 6.0–
6.3) in Korea to 7.2 mmol/l (6.8–7.6) in
Nauru (Fig. 1). Pooling the five meaning-
ful cut points, the overall cut point for
normal glycemia was estimated to be 6.7
mmol/l (6.5–6.9) (Fig. 2). This result is
somewhat lower than the WHO diabetes
diagnostic cut point for fasting plasma
glucose of 7.0 mmol/l. Removing Singa-
pore (where bimodality was not signifi-
cant) from the pooled analysis decreased
the overall estimated cut point by 0.2
mmol/l.
For 2-h plasma glucose, 8 of 26 coun-
tries (30%) produced a meaningful cut
point. Except for Sweden, Spain, and
Tonga, the mixture model was statistically
superior (Table 2). The estimated cut
points ranged from 8.5 mmol/l (95% CI
7.6–9.5) in Egypt to 12.7 mmol/l (7.6–
14.9) in Taiwan (Fig. 1). The overall cut
point was 11.0 mmol/l (10.6–11.4) (Fig.
2). This result corresponds to the WHO
diabetes diagnostic cut point for 2-h
plasma glucose of 11.1 mmol/l. Removing
Sweden, Spain, and Tonga from the
pooled analysis decreased the overall es-
timated cut point by 0.2 mmol/l.
Analyses including patients with
known diabetes
All countries except two had measure-
ments of FPG in participants with known
diabetes (n  103,410). Repeating the
analyses for FPG including patients with
known diabetes, 11 of 25 countries (44%)
now produced a meaningful cut point. In
only one of these 11 countries (Singa-
pore) was the mixture model not statisti-
cally superior to the unimodal model
(Table 2). The pooled cut point was 6.8
mmol/l (95% CI 6.7–6.8) both with and
Figure 1—Distribution of FPG in Korea (A) and Nauru (B) and 2-h plasma glucose in Egypt (C) and Taiwan (D). Patients with known diabetes
are excluded. The histograms represent data (intervals of 0.2 mmol/l). The superimposed solid curve is the fitted mixture model, and the dotted curves
are the two underlying distributions.
Bimodality in glucose
400 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009
without Singapore, which is consistent
with the result found when patients with
known diabetes were excluded. In addi-
tion, the range in cut points was compa-
rable: from 6.4 mmol/l (5.9–6.7) in India
to 7.4 mmol/l (6.9–7.7) in Nauru.
Ten studies from eight different coun-
tries had measurements of 2-h plasma
glucose in participants with known dia-
betes (n  18,872). Of these, five (63%)
produced a meaningful cut point for nor-
mal glycemia, and, in addition, the mix-
ture model was significantly superior in
Egypt, India, and the U.S. (Table 2). The
corresponding pooled cut point was 10.9
mmol/l (95% CI 8.3–11.3), which was re-
duced by 0.6 mmol/l when Sweden and
Japan, which had nonsignificant mixture
models, were removed from the analysis.
This result is also consistent with the re-
sult found when patients with known di-
abetes were excluded but with a greater
range in the individual cut points from
8.2 mmol/l (7.8–8.7) in India to 13.6
mmol/l (12.8–14.7) in Sweden.
CONCLUSIONS— When known di-
abetes was excluded from the analysis, re-
sults from less than one-third of the
countries were useful for deriving a cut
point for normal glycemia in FPG and 2-h
plasma glucose. Consequently, when
known diabetes is removed, distributions
of plasma glucose do not commonly give
rise to a bimodal structure that is useful
for deriving a cut point for diabetes. In-
clusion of participants with known diabe-
tes, although not universally present,
more than doubled this proportion to
44% for FPG and 63% for 2-h plasma glu-
cose. In most countries with a meaningful
cut point, the mixture model was signifi-
cantly superior to the unimodal normal
model. This test was, however, based on a
	2 distribution with 4 d.f. to err on the
side of rejecting unimodality in favor of
bimodality. These results indicate that the
presence of a biologically meaningful bi-
modal structure in glucose seems to be
driven by patients with known diabetes.
The overall pooled cut points for nor-
mal glycemia were almost invariant to
whether or not participants with known
diabetes were included. However, the es-
timated cut points were inconsistent be-
tween countries, especially for 2-h plasma
glucose when participants with known
diabetes were included. Comparing these
results with those of earlier studies, we
found that the overall cut point for FPG
was somewhat lower (2,3,8,9), whereas
the cut point for 2-h plasma glucose was
well in line (1–3,5,8,10,11,13), except for
the studies of South African Indians (9)
and Western Samoans (12), which pro-
duced lower cut points for 2-h plasma
glucose.
Earlier studies reported that bimodal
structure in glucose distribution is more
pronounced in the older age-groups, in
whom the prevalence of diabetes is higher
(1,2,5,8,9,11,12). We addressed the pos-
sible effect of age by considering the sub-
population aged 60 years (data not
shown). In general, our main results were
reproduced in this age-group. Only very
few additional countries produced a bio-
logically meaningful cut point, but again,
including patients with known diabetes
increased the proportion of meaningful
bimodal structures. This finding is in line
with an earlier study showing the mean of
the upper normal component to be simi-
lar in different age-groups (4).
To increase sample size, we also
pooled populations that were geographi-
cally in the same ethnic area: Caucasians,
Africans, Asians, and Pacific Islanders
(data not shown). A meaningful bimodal
structure of data was only detected in half
of the ethnic areas.
Excluding participants with known
diabetes from the analyses reduces the
prevalence of diabetes in the population
by 50%, which may prohibit a signifi-
cant fit of the mixture model. In addition,
Figure 2—Cut points (95%CI) for normal glycemia in glucose. The gray and black lines represent analyses with andwithout individuals with known
diabetes. The dotted vertical line is the WHO 1999 cut point for diabetes. *Statistically significant mixture model.
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the mean of the second component is
likely to be lower when patients with
known diabetes that is more advanced are
excluded. This exclusion potentially
makes the two components less distinct
and thereby decreases the probability of a
meaningful cut point separating them.
However, as acknowledged in previous
studies (3,10,13), including patients with
known diabetes in the analyses will in-
duce a treatment bias for the following
reasons. In accordance with existing treat-
ment guidelines, patients with diabetes
are treated with the aim of lowering their
glucose to a near-normal range. This im-
plies that diabetic patients with higher
glucose values are treated relatively more
aggressively than patients with only
slightly raised glucose values. It seems
reasonable to assume that aggressively
treated patients have a larger absolute de-
crease in glucose values than patients who
are treated less aggressively (19). There-
fore, the effect of treatment is not an equal
shift to the left in the glucose distribution
of the entire diagnosed population but,
rather, a shift that increases with glucose
values at diagnosis (20). Hence, the glu-
cose values of the subgroup with the high-
est values is shifted toward the glucose
values of the rest of the diagnosed popu-
lation. This means that patients with di-
agnosed diabetes are bunched together,
thereby potentially creating an artificial
bimodal structure in the glucose data.
How do we overcome this problem?
The ideal setting for studying bimodality
in glucose distribution is a treatment-
naive population (including diabetes
treatment) in whom diabetes is undiag-
nosed. This is not the case in any of the
studies in this analysis. A theoretical solu-
tion to the problem is to adjust the mea-
sured glucose value of a treated patient to
its untreated level. This would require
knowledge of the exact effect of treatment
for each patient. However, different doc-
tors may prescribe different treatments to
patients with the same glucose levels. In
addition, even if the same treatment is ad-
ministered, its effect will vary among pa-
tients because of differences in phenotype
as well as in adherence to treatment.
Hence, adjusted glucose values are highly
uncertain. A study from Malaysia (10)
suggested imputing glucose values for the
patients with known diabetes using the
measured glucose values of the partici-
pants with SDM in the same population
and taking into account age, sex, ethnic-
ity, and medical history of diabetes status.
The model does not account for diabetes
duration. However, glucose is known to
increase with diabetes duration despite
increasing treatment (21). Participants
with SDM have, by definition, newly di-
agnosed diabetes, whereas patients with
known diabetes may have had the diag-
nosis several years previously, which
questions the validity of imputing their
glucose values based on those of partici-
pants with SDM.
In summary, this study has shown
that distributions of FPG and 2-h plasma
glucose, in general, do not give rise to a
bimodal structure that is useful for deriv-
ing a cut point for diabetes in populations
of different origin. Including patients
with known diabetes increases the possi-
bility of deriving a meaningful cut point,
but the bimodal structure in data may be
a treatment artifact. In addition, cut
points produced for normal glycemia
were inconsistent over geographical re-
gions. Thus, bimodality is not a suitable
method for defining diagnostic cut points
for diabetes. Instead, it seems more rele-
vant to base the diagnostic criteria on
thresholds for diabetes-specific micro-
and macrovascular complications. How-
ever, further analyses are needed in this
area.
Acknowledgments— The DETECT-2 proj-
ect was undertaken on the initiative of the
World Health Organization and the Interna-
tional Diabetes Federation.
No potential conflicts of interest relevant to
this article were reported.
APPENDIX
DETECT-2 Writing Committee for this
article. Dorte Vistisen, MSc, PhD, Steno
Diabetes Center, Gentofte, Denmark;
Prof. Stephen Colagiuri, MD, Department
of Medicine, University of Sydney, Syd-
ney, Australia; and Prof. Knut Borch-
Johnsen, DMSc, Steno Diabetes Center,
Gentofte, Denmark.
DETECT-2 Steering Committee. S. Co-
lagiuri (Australia), K. Borch-Johnsen
(Denmark), G. Alberti (U.K.), R. Williams
(U.K.), G. Roglic (Switzerland), B. Balkau
(France), A. Ramachandran (India), and J.
Tuomilehto (Finland).
Principal investigators of the studies. P.
Zimmet and J. Shaw (Australia); L. Fezeu
(Cameroon); T. Jørgensen and K. Borch-
Johnsen (Denmark); B.P. Tabai (Egypt); J.
Tuomilehto and R. Tilvis (Finland); E. Es-
chwege and B. Balkau (France); W. Rath-
mann (Germany); P. Bjerregaard
(Greenland); V. Mohan, S.R. Iyer, and A.
Ramachandran (India); G. Semiardji (In-
donesia); R. Dankner (Israel); M. Tomi-
naga (Japan); N.H. Cho and H.L. Kim
(Korea); P. Zimmet and J. Shaw (Mauri-
tius, Nauru); B. Wang and Y. Dong (Chi-
na); Z. Szybinski (Poland); S. Viali
(Samoa); J. Cutter (Singapore); P.L. de
Pablos-Velasco (Spain); M. Eliasson and
B. Zethelius (Sweden); P. Chou (Taiwan);
J.M. Dekker, G. Nijpels, and E.J.M.
Feskens (the Netherlands); T. Palu and
S. Colagiuri (Tonga); N. Wareham, Sir
K.G.M.M. Alberti, and M. Marmot (U.K.);
Y.J. Cheng, M. Engelgau, and M.I. Schmidt
(U.S.); and T.V. Binh (Vietnam). See on-
line appendix for details.
References
1. Rushforth NB, Bennett PH, Steinberg AG,
Burch TA, Miller M: Diabetes in the Pima
Indians: evidence of bimodality in glucose
tolerance distributions. Diabetes 20:756–
765, 1971
2. Zimmet P, Whitehouse S: Bimodality of
fasting and two-hour glucose tolerance
distributions in a Micronesian popula-
tion. Diabetes 27:793–800, 1978
3. Engelgau MM, Thompson TJ, Herman
WH, Boyle JP, Aubert RE, Kenny SJ, Bad-
ran A, Sous ES, Ali MA: Comparison of
fasting and 2-hour glucose and HbA1c lev-
els for diagnosing diabetes: diagnostic cri-
teria and performance revisited. Diabetes
Care 20:785–791, 1997
4. Thompson TJ, Smith PJ, Boyle JP: Finite
mixture-models with concomitant infor-
mation-assessing diagnostic-criteria for
diabetes. J Roy Stat Soc C 47:393–404,
1998
5. Rosenthal M, McMahan CA, Stern MP, Ei-
fler CW, Haffner SM, Hazuda HP, Franco
LJ: Evidence of bimodality of two hour
plasma glucose concentrations in Mexi-
can Americans: results from the San An-
tonio Heart study. J Chronic Dis 38:5–16,
1985
6. World Health Organization: WHO Expert
Committee on Diabetes Mellitus: Second Re-
port. Geneva, World Health Org., 1980
(Tech. Rep. Ser., no. 646)
7. World Health Organization: Diabetes Mel-
litus: Report of a WHO Study Group. Ge-
neva, World Health Org., 1985 (Tech.
Rep. Ser., no. 727)
8. Dowse GK, Spark RA, Mavo B, Hodge
AM, Erasmus RT, Gwalimu M, Knight LT,
Koki G, Zimmet PZ: Extraordinary prev-
alence of non-insulin-dependent diabetes
mellitus and bimodal plasma glucose dis-
tribution in the Wanigela people of Papua
New Guinea. Med J Aust 160:767–774,
1994
9. Omar MA, Seedat MA, Dyer RB, Motala
AA, Knight LT, Becker PJ: South African
Indians show a high prevalence of
Bimodality in glucose
402 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009
NIDDM and bimodality in plasma glucose
distribution patterns. Diabetes Care 17:
70–73, 1994
10. Lim TO, Bakri R, Morad Z, Hamid MA:
Bimodality in blood glucose distribution:
Is it universal? Diabetes Care 25:2212–
2217, 2002
11. Loo SG, Dowse GK, Finch C, Zimmet P: Bi-
modalityanalysisof frequencydistributionsof
2-hour plasma glucose concentrations in the
urban Micronesian population of Kiribati. J
Diabetes Complications 7:73–80, 1993
12. Raper LR, Taylor R, Zimmet P, Milne B,
Balkau B: Bimodality in glucose tolerance
distributions in the urban Polynesian
population of Western Samoa. Diabetes
Res 1:19–26, 1984
13. Fan J, May SJ, Zhou Y, Barrett-Connor E:
Bimodality of 2-h plasma glucose distribu-
tions in whites: the Rancho Bernardo study.
Diabetes Care 28:1451–1456, 2005
14. Colagiuri S, Borch-Johnsen K: DE-
TECT-2: early detection of type 2 diabetes
and IGT. Diabetes Voice 48:11–13, 2003
15. World Health Organization: Definition, Di-
agnosis and Classification of Diabetes Mellitus
and Its Complications: Report of a WHO Con-
sultation, Part 1: Diagnosis and Classification
of Diabetes Mellitus. Geneva, World Health
Org., 1999 (WHO/NCD/NCS/99.2)
16. Titterington DM, Smith AFM, Makov UE:
Statistical Analysis of Finite Mixture Distri-
butions. New York, Wiley, 1985
17. McLachlan GJ: On bootstrapping the like-
lihood ratio test statistic for the number of
components in a normal mixture. Appl
Stat 36:318–324, 1987
18. Efron B, Tibshirani RJ: An Introduction to
the Bootstrap. New York, Chapman &
Hall, 1993
19. Manley S: Haemoglobin A1c: a marker for
complications of type 2 diabetes: the ex-
perience from the UK Prospective Diabe-
tes Study (UKPDS). Clin Chem Lab Med
41:1182–1190, 2003
20. Hayward RA, Manning WG, Kaplan SH,
Wagner EH, Greenfield S: Starting insulin
therapy in patients with type 2 diabetes:
effectiveness, complications, and re-
source utilization. JAMA 278:1663–1669,
1997
21. Turner RC, Holman RR, Cull CA, Stratton
IM, Matthews DR, Frighi V, Manley SE, Neil
A, McElroy H, Wright D, Kohner E, Fox C,
Hadden D: Intensive blood-glucose control
with sulphonylureas or insulin compared
with conventional treatment and risk of
complications in patients with type 2 diabe-
tes (UKPDS 33). Lancet 352:837–853,
1998
Vistisen and Associates
DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009 403
